Crossmark

Intravenous cyclophosphamide as an alternative to the oral cyclophosphamide modified Ponticelli regimen for high-risk PLA2R-positive membranous nephropathy

Crossref DOI link: https://doi.org/10.1007/s40620-022-01426-6

Published Online: 2022-08-12

Published Print: 2023-03-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Ștefan, Gabriel

Zugravu, Adrian

Stancu, Simona
License Information

Version of Record valid from 2022-08-12

Text and Data Mining valid from 2022-08-12

Version of Record valid from 2022-08-12
More Information

Article History

Received: 13 June 2022

Accepted: 29 July 2022

First Online: 12 August 2022

Declarations

:

: None of the authors has conflicts of interest.

: The study complies with the guidelines for human studies and the research was conducted ethically in accordance with the World Medical Association Declaration of Helsinki.

Document is current

Any future updates will be listed below